Apr 2024 Articles

Articles
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Bonaca MP, Bhatt DL, Simon T, et al.
Journal:
J Am Coll Cardiol

First published: April 30, 2024 DOI: 10.1016/j.jacc.2024.03.377
View
- Share
Articles
Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)
Razavi AC, Richardson LC, Coronado F, et al.
Journal:
Am J Prev Cardiol

First published: April 27, 2024 DOI: 10.1016/j.ajpc.2024.100674
View
- Share
Articles
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Burger PM, Bhatt DL, Dorresteijn JAN, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 27, 2024 DOI: 10.1093/ehjcvp/pvae030
View
- Share
Articles
Empagliflozin after Acute Myocardial Infarction
Butler J, Jones WS, Udell JA, et al.
Journal:
N Engl J Med

First published: April 25, 2024 DOI: 10.1056/NEJMoa2314051
View
- Share
Articles
Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar R, Katz ME, Grandhi GR, et al.
Journal:
Curr Atheroscler Rep

First published: April 25, 2024 DOI: 10.1007/s11883-024-01202-w
View
- Share
Articles
Targeting immune cell recruitment in atherosclerosis
Döring Y, van der Vorst EPC, Weber C
Journal:
Nat Rev Cardiol

First published: April 25, 2024 DOI: 10.1038/s41569-024-01023-z
View
- Share
Articles
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation
Goodman SG, Steg PG, Szarek M, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 24, 2024 DOI: 10.1093/ehjcvp/pvae025
View
- Share
Articles
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Szarek M, Bhatt DL, Miller M, et al.
Journal:
J Am Coll Cardiol

First published: April 23, 2024 DOI: 10.1016/j.jacc.2024.02.016
View
- Share
Articles
Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction
Ichikawa K, Wang R, McClelland RL, et al.
Journal:
Heart

First published: April 23, 2024 DOI: 10.1136/heartjnl-2023-323838
View
- Share
Articles
Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial
Sayed A, Brophy JM
Journal:
Int J Cardiol

First published: April 19, 2024 DOI: 10.1016/j.ijcard.2024.132074
View
- Share
Articles
Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary
Gu J, Gupta RN, Cheng H, et al.
Journal:
Eur J Prev Cardiol

First published: April 18, 2024 DOI: 10.1093/eurjpc/zwae144
View
- Share
Articles
Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease
Holtrop J, Bhatt DL, Ray KK, et al.
Journal:
Eur J Prev Cardiol

First published: April 18, 2024 DOI: 10.1093/eurjpc/zwae038
View
- Share

1 2

Apr 2024 Articles

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Articles

Targeting immune cell recruitment in atherosclerosis

Döring Y, van der Vorst EPC, Weber C

Articles

Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

Goodman SG, Steg PG, Szarek M, et al.

Articles

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Szarek M, Bhatt DL, Miller M, et al.

Articles

Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction

Ichikawa K, Wang R, McClelland RL, et al.

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Articles

Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary

Gu J, Gupta RN, Cheng H, et al.

Articles

Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Holtrop J, Bhatt DL, Ray KK, et al.

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Share

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Share

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Share

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Share

Articles

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

Mszar R, Katz ME, Grandhi GR, et al.

Share

Articles

Targeting immune cell recruitment in atherosclerosis

Döring Y, van der Vorst EPC, Weber C

Share

Articles

Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

Goodman SG, Steg PG, Szarek M, et al.

Share

Articles

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Szarek M, Bhatt DL, Miller M, et al.

Share

Articles

Thoracic versus coronary calcification for atherosclerotic cardiovascular disease events prediction

Ichikawa K, Wang R, McClelland RL, et al.

Share

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Share

Articles

Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary

Gu J, Gupta RN, Cheng H, et al.

Share

Articles

Impact of the 2021 European Society for Cardiology prevention guideline’s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease

Holtrop J, Bhatt DL, Ray KK, et al.

Share